Researcher Spotlight: Elisa Mandato, PhD DANA-FARBER CANCER INSTITUTE Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and the most common hematologic malignancy in the United States. Dr. Mandato’s LRF research project will involve developing…
Researcher Spotlight: Alexandre Vinaud Hirayama, MD Fred Hutchinson Cancer Research Center Chimeric antigen receptor (CAR) T cell therapy is a typeof immunotherapy that genetically modifies a patient’simmune cells to recognize and kill tumor cells. “CAR T cell therapy has shown…
Researcher Spotlight: Rui Guo, PhD Brigham and Women’s Hospital, Harvard Medical School Epstein-Barr virus (EBV) was the first virus found to causeBurkitt lymphoma, a rare and aggressive form of non-Hodgkin lymphoma (NHL). The virus shuts down nearlyall its genes in…
Researcher Spotlight: Edmond Feris, PhD Dartmouth-Hitchcock Norris Cotton Cancer Center Some of the most critical oncogenes responsible fortumor formation in humans are transcription factors. Dr.Feris’ LRF research project focuses on the study of howtranscriptional dysregulation can lead to carcinogenesis(the process…
Researcher Spotlight: Elena Battistello, PhD New York University School of Medicine Peripheral T-cell lymphoma (PTCL) is an aggressive type of non-Hodgkin lymphoma (NHL) derived from the malignant transformation of blood cells called T-lymphocytes. Currently, patients diagnosed with PTCL have limited…
Researcher Spotlight: Reid Merryman, MD, MS Dana-FArber Cancer Institute Classical Hodgkin lymphoma (cHL) tumor cells have developed several ways to avoid detection and destruction by the immune system, including expression of immune checkpoint proteins on their surface to shield them…
Researcher Spotlight: Xu Cao, PhD City of Hope and Beckman Research Institute Many types of non-Hodgkin lymphoma (NHL) remain incurable due to its intrinsic genomic instability facilitating the escape from cytotoxic or targeted therapies. “Recent breakthroughs in understanding macrophage-mediated immune…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Researcher Spotlight: Ryan Lynch, MD University of Washington Checkpoint inhibitors, a type of immunotherapy, have been approved for patients with relapsed Hodgkin lymphoma (HL); however, they do not lead to durable remissions in most patients. Dr. Lynch’s LRF grant project…